Study of Alternate Treatments Before Surgery for Early Stage Breast Cancer Patients

What we are studying

To determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing.

Who we are studying

  • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Postmenopausal
  • ER positive
  • HER2 negative
  • Stage II or III breast cancer

What is involved

  • Biopsies
  • Exams
  • Mammograms
  • Ultrasounds
  • Assigned randomly to one of three study drug options

Contact Information

Study Coordinator
Michele Harmon
Email
mharmon@wakehealth.edu
Phone
336-713-6925

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.